MK-5172 sodium salt (MK-5172 sodium salt) 是丙型肝炎病毒 NS3/4a 蛋白酶的选择性抑制剂，对基因型和耐药变异具有广泛的活性，Kis 为 0.01 nM (gt1b)、0.01 nM (gt1a)、0.08 nM (gt2a)、0.15 nM (gt2b)、0.90 nM (gt3a)。
| Cas No. |
1425038-27-2 |
| 别名 |
MK5172 sodium salt;MK 5172 sodium salt |
| Canonical SMILES |
CC(C)(C1C(N2CC(OC3=NC4=C(N=C3CCCCCC5CC5OC(N1)=O)C=CC(OC)=C4)CC2C(NC6(C(NS(=O)(C7CC7)=O)=O)CC6C=C)=O)=O)C.[Na+] |
| 分子式 |
C38H50N6NaO9S+ |
| 分子量 |
789.89 |
| 溶解度 |
Soluble in DMSO |
| 储存条件 |
Store at -20℃ |
| General tips |
For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition |
Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 半岛bd体育手机客户端 描述 |
IC50 Value: 7.4nM and 7nM for genotype1b and 1a respectively, in replicon system [1] MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development. in vitro: In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a [2]. in vivo: In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose [1]. Clinical trial: Evaluation of Hepatic Pharmacokinetics for MK-5172 in Participants With Chronic Hepatitis C . Phase1 |
m.cnreagent.com
